Chemiluminescent FemtoMax^TM Super Sensitive HRP Substrate for Microwell and/or Membrane  

Chemiluminescent FemtoMax？ Super Sensitive HRP Substrate for Microwell and/or Membrane (2 component system)

Western blot detection using Chemiluminescent FemtoMaxTM HRP Substrate. rPARP1 domain detected at 11 kDa after 3 sec exposure using primary antibody rabbit anti-serum 1:500 overnight, at 4C. Secondary antibody Peroxidase Goat Anti‐Rabbit IgG Antibody at 1:40,000. All incubations were performed in Blocking Buffer for Fluorescent Western Blocking (p/n MB‐070).

Western Blot of anti-GST tag antibody. Lane 1: Recombinant GST tagged recombinant protein 5 ug. Lane 2: Recombinant GST tagged recombinant protein 2 ug. Lane 3: Recombinant GST tagged recombinant protein 1 ug. Lane 4: Recombinant GST tagged recombinant protein 500 ng. Lane 5: Recombinant GST tagged recombinant protein 250 ng. Lane 6: Recombinant GST tagged recombinant protein 100 ng. Lane 7: Recombinant GST tagged recombinant protein 50 ng. Primary antibody: anti-GST antibody at 1:1000 for overnight at 4°C. Secondary antibody: donkey secondary antibody at 1:10,000 for 45 min at RT. Block: 5% BLOTTO overnight at 4°C. Predicted/Observed size: 78 kDa.

Concentration of plasma MDS-OAβ according to groups.The incubated plasma sample mixture and serially diluted standard samples were added to respective wells, and the plates were incubated at room temperature for 1 hour. Afterwards, 100 μL/well of enhanced chemiluminescence substrate solution (p/n Femtomax) was added, and the Relative Luminescence Unit (RLU) signal was detected using a Victor 3TM？multi-spectrophotometer.？Abbreviations:？AD, Alzheimer’s disease; MCI, mild cognitive impairment; MDS-OAβ, Multimer Detection System-Oligomeric Amyloid-β; OND, other neurodegenerative disease; SCD, subjective cognitive decline.Fig 1. PMID: 33958861.

Effect of CK2.3 on p-Erk 1/2 in RANKL-induced osteoclastogenesis. CK2.3 increased p-Erk 1/2 after 24 h of stimulation in RAW264.7 cells, as determined by (A) Western blotting. The blot was incubated in 3% BSA for 1 h to block non-specific binding. Antibodies used at 1:1000 dilutions (in 1% BSA) overnight at 4 °C. Followed by incubation with the secondary antibody HRP anti-rabbit at a 1:5000 dilution (in 1% BSA). The blot was incubated in Chemiluminescent FemtoMax Super Sensitive HRP Substrate (p/n Femtomax) for 2 min. Fig 6. PMID: 32660129.

The subtests of the Korean version of Consortium to Establish a Registry for Alzheimer’s disease (CERAD-K) and plasma oligomerized beta amyloid (OAβ). (a) Raw scores of the CERAD-K and OAβ concentration. (b) The abnormal CERAD group (below −1.5 standard deviation of age/sex/education adjusting norms) in verbal fluency, naming, word memory/recall, and total scores showed higher OAβ concentration compared with control. (c) Abnormality in naming, word memory/recall/recognition, and total scores are significantly more frequent in high OAβ groups (？ 0.78 ng/mL). SD―standard deviation; VF―verbal fluency; BN―Boston naming; MMSE―mini-mental status examination; WM―word list memory; CP―constructional praxis; WRL―word list recall; WRN―word list recognition; and PR―praxis recall. Total I is a sum of subtests except MMSE and PR and Total II is a sum except MMSE. *？p？< 0.05. **？p？< 0.01.To increase the sensitivity of detection, 100 μL/well of enhanced chemiluminescence substrate solution (p/n Femtomax) was added, and the Relative Luminescence Unit (RLU) signal was detected using a Victor 3TM？multi-spectrophotometer.Fig 2. PMID: 32326061.